Evidence-Based Guidelines for the Pharmacological Management of Acute Methamphetamine-Related Disorders and Toxicity
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Consumption of methamphetamine (“crystal”) has spread dramatically over several European countries. The management of methamphetamine-induced acute disorders has become a growing challenge to the health system. Pharmacological treatment strategies for methamphetamine-induced intoxication syndromes, acute withdrawal symptoms, and methamphetamine-induced psychosis are particularly important. The development of interdisciplinary and evidence- and consensus-based (S3) German Guidelines was based on a systematic literature and guideline search on therapeutic interventions in methamphetamine-related disorders (April, June 2015). Consideration was given to 9 guidelines and 103 publications. Recommendations on pharmacological treatment strategies were drawn up using the nominal group technique. Overall, only limited evidence is available. Benzodiazepines are first-line medication for methamphetamine-induced intoxication syndromes, particularly when they present with acute agitation and aggressive behavior. There is no evidence-based medication for the treatment of methamphetamine-related withdrawal symptoms and cravings. When treating methamphetamine-induced psychosis, second-generation antipsychotics should be favored, given their more favorable side-effect profile. The indication for continuation of antipsychotic medication must be reviewed regularly. In most cases, the antipsychotic should be tapered off within 6 months.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The nature, time course and severity of methamphetamine withdrawal
McGregor, C., Srisurapanont, M., Jittiwutikarn, J., Laobhripatr, S., Wongtan, T., & White, J. M. (2005) · Addiction · doi:10.1111/j.1360-0443.2005.01160.x · Cited by 458 · cited 2×
“Treatment of a methamphetamine withdrawal should be at least 3 weeks, particularly in the case of high and regular substance con - sumption (LoE 5; ⇑⇑ ) [14, 18].”
BackgroundLongo, M., Wickes, W., Smout, M., Harrison, S., Cahill, S., & White, J. M. (2010) · Addiction · doi:10.1111/j.1360-0443.2009.02717.x · Cited by 122
Kishi, T., Matsuda, Y., Iwata, N., & Correll, C. U. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13r08525 · Cited by 77
A placebo‐controlled trial of mirtazapine for the management of methamphetamine withdrawal
CRUICKSHANK, C. C., MONTEBELLO, M. E., DYER, K. R., QUIGLEY, A., BLASZCZYK, J., TOMKINS, S., & SHAND, D. (2008) · Drug and Alcohol Review · doi:10.1080/09595230801935672 · Cited by 74
A review of treatment options for co-occurring methamphetamine use disorders and depression
Hellem, T. L., Lundberg, K. J., & Renshaw, P. F. (2015) · Journal of Addictions Nursing · doi:10.1097/jan.0000000000000058 · Cited by 51 · cited 2×
“Another study (n = 31) failed to show any effect of mirtazapine on retention rate or withdrawal symptoms such as sleep disorders, anxiety, and depression [20–22].”
BackgroundHester, R., Lee, N., Pennay, A., Nielsen, S., & Ferris, J. (2010) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0021791 · Cited by 42 · cited 2×
“For other stimulants, either no evidence was available for the acute treatment of methamphetamine-dependent users (methyl - phenidate), or the available studies did not show any effects or they only showed marginal benefits compared to placebo [32–36].”
BackgroundJohnson, B. A., Roache, J. D., Ait-Daoud, N., Wallace, C., Wells, L. T., & Wang, Y. (2005) · Psychopharmacology · doi:10.1007/s00213-004-1998-0 · Cited by 33 · cited 1×
“However, israpidine was not well tolerated during methamphetamine withdrawal [38].”
BackgroundGalloway, G. P., Singleton, E. G., The Methamphetamine Treatment Project Corporate Authors, Anglin, M. D., Rawson, R. A., Patricia, M.-C., Joseph, B., Richard, B., Alison Hamilton, B., Cynthia, B., et al. (2008) · Substance Abuse: Research and Treatment · doi:10.4137/sart.s775 · Cited by 24
Cited by
Pharmacological Treatment of Methamphetamine/Amphetamine Dependence: A Systematic Review
Siefried, K. J., Acheson, L. S., Lintzeris, N., & Ezard, N. (2020) · CNS Drugs · doi:10.1007/s40263-020-00711-x · Cited by 194
Srisurapanont, M., Likhitsathian, S., Suttajit, S., Maneeton, N., Maneeton, B., Oon‐arom, A., & Suradom, C. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2020.108467 · Cited by 26
Hamel, C., Corace, K., Hersi, M., Rice, D., Willows, M., Macpherson, P., Sproule, B., Flores-Aranda, J., Garber, G., Esmaeilisaraji, L., et al. (2020) · Systematic Reviews · doi:10.1186/s13643-020-01499-z · Cited by 17
Metadata
- Authors
- Wodarz, N., Krampe-Scheidler, A., Christ, M., Fleischmann, H., Looser, W., Schoett, K., Vilsmeier, F., Bothe, L., Schaefer, C., & Gouzoulis-Mayfrank, E.
- Venue
- Pharmacopsychiatry
- Publisher
- Georg Thieme Verlag KG
- Published
- 2017-03-15
- Volume
- 50
- Issue
- 03
- Pages
- 87-95
- ISSN
- 0176-3679 (ISSN-L)
- 1439-0795
- OpenAlex
- W2599327775
- Cited by
- 40
- References
- 8
- FWCI
- 3.15
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evidence-Based Guidelines for the Pharmacological Management of Acute Methamphetamine-Related Disorders and Toxicity. https://app.cochat.ai/papers/10.1055/s-0042-123752
- The paper
- Wodarz, N., Krampe-Scheidler, A., Christ, M., Fleischmann, H., Looser, W., Schoett, K., Vilsmeier, F., Bothe, L., Schaefer, C., & Gouzoulis-Mayfrank, E. (2017). Evidence-Based Guidelines for the Pharmacological Management of Acute Methamphetamine-Related Disorders and Toxicity. Pharmacopsychiatry. https://doi.org/10.1055/s-0042-123752
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.